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Histonedeacetylase inhibitors(HDACi)representapromisingavenuefor cancertherapy.Weappliedmass
spectrometry (MS) to determine the impact of clinically relevant HDACi on global levels of histone
acetylation. Intact histone profiling revealed that the HDACi SAHA and MS-275 globally increased histone
H3 and H4 acetylation in both normal diploid fibroblasts and transformed human cells. Histone H3 lysine
56acetylation (H3K56ac)recentlyelicitedmuchinterestandcontroversyduetoitspotentialasadiagnostic
and prognostic marker for a broad diversity of cancers. Using quantitative MS, we demonstrate that
H3K56ac is much less abundant than previously reported in human cells. Unexpectedly, in contrast to
H3/H4 N-terminal tail acetylation, H3K56ac did not increase in response to inhibitors of each class of
HDACs. In addition, we demonstrate that antibodies raised against H3K56ac peptides cross-react against
H3 N-terminal tail acetylation sites that carry sequence similarity to residues flanking H3K56.
E
ukaryotic DNA is packaged into a nucleoprotein structure known as chromatin. The primary function of
this structure is to compact DNA within the cell nucleus. The fundamental repeating unit of chromatin is
the nucleosome core particle (NCP), which is composed of 147 base pairs of DNA wrapped nearly twice
around the surface of an octamer of small basic proteins known as histones
1. This octamer is formed from two
molecules each of four types of core histones: H2A, H2B, H3, and H4. Although the structure of chromatin is
inherently dynamic, it also considerably restricts access to genetic information
2. Cells have evolved mechanisms
to control access to DNA packaged into chromatin. These include ATP-driven nucleosome remodeling
machines, histone variants and histone post-translational modifications (PTMs)
3. Each core histone consists
of a conformationally flexible N-terminal extension, commonly referred to as ‘‘histone tail’’, and a globular
domain that mediates protein-protein interactions and DNA binding within NCPs
1. The N-terminal tails of
corehistonesprotrudebeyondtheDNAgyresofNCPs,andarethereforereadilyaccessibletohistone-modifying
enzymes
1.ThesetaildomainscontainmultipleresiduesthatarecovalentlymodifiedbyawidediversityofPTMs
3.
Advances in mass spectrometry (MS) have also uncovered a number of PTMs in the globular domains of core
histones
4–6. Histone PTMs occur either alone or in combination, leading to the notion of a ‘‘histone code’’, a
generic term used to describe how specific patterns of histone PTMs influence the binding of effector proteins to
NCPs and, as a result, control a variety of processes that require access to DNA
7.
One of the most intensively studied histone PTMs is the acetylation of lysine residues
3. The addition and
removal of an acetyl group on lysine residues, respectively mediated by histone acetyltransferases (HATs) and
deacetylases (HDACs), is a highly dynamic and regulated process that contributes to transcriptional activation
andsilencing
8.Inhumans,thereare18knownHDACenzymesthataresubdividedintofourclasses
9.Theseminal
discovery that the histone deacetylase inhibitor (HDACi) trichostatin A (TSA) triggered cell cycle arrest and
differentiation of Friend erythroleukaemic cells promoted numerous subsequent studies on various types of
cancer cells
10. In diseases such as cancer, HDACs contribute to oncogenesis via at least two distinct mechanisms:
overexpression of individual HDACs
11, and aberrant recruitment of HDACs to specific chromosomal loci by
oncogenic fusion proteins (e.g. PML-RARa)
12. These perturbations of HDAC function often lead to silencing of
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tonePTMsalsooccurincancercells.Forexample,astudyofnumer-
ous cancer cell lines, normal tissues and primary tumors revealed
that a global decrease in H4K16 acetylation and H4K20 methylation
is a recurring feature of many types of cancer cells
13.
The involvement of HDACs in cancer has raised hope that these
enzymes may represent valuable targets in drug discovery programs.
Recent clinical trials demonstrated that, at least for hematological
cancers
14–16, small molecules that inhibit HDACs can be effec-
tive pharmacological agents, either when administered alone or in
combination with other drugs
17. HDACi exhibit a number of anti-
proliferativeeffects,such ascell cycle arrest, differentiation, angiogen-
esis inhibition and apoptosis.
9,18 A significant number of HDACi,
such as suberoylanilide hydroxamic acid (SAHA, also known as
vorinostat or Zolinza), entinostat (MS-275), romidepsin (Istodax),
and belinostat (PXD-101) are at various stages of drug development.
At present, only SAHA
19 and romidepsin
20 have been approved by
the US food and drug administration for treatment of cutaneous
T-cell lymphoma. HDACi such as SAHA are non-selective
21.
There is a growing debate over the use of HDACi that cause non-
specific inhibition of several distinct HDACs versus development of
HDACi that would target specific classes of enzymesor even perhaps
a single enzyme. In addition to histones, HDACs deacetylate many
important protein substrates, such as transcription regulators (e.g.
p53, Rb, E2F1 and nuclear hormone receptors)
18. Thus, inhibiting
multiple HDACs could be cytotoxic to normal cells and lead to
undesirable side effects. On the other hand, it can be argued that
non-selective HDACi are effective at killing cancer cells precisely
because they interfere with the deacetylation of multiple substrates.
Currently, it is not known whether inhibition of histone deacetyla-
tion, as opposed to other protein substrates, plays a major role in the
anti-neoplastic effects of non-selective HDACi. As a first step to
address these difficult questions, it is important to determine to what
extent HDACi impair histone deacetylation in normal and cancer
cells.
The ability to determine stoichiometric changes in histone acet-
ylation elicited by HDACi is of paramount importance to identify
their enzyme targets and therapeutically relevant protein substrates.
Moreover,abetter understanding of HDACi-induced changes inthe
abundance of histone acetylation at specific lysine residues could
facilitate biomarker discovery and monitoring of the therapeutic
effects of HDACi
22. Due to its sensitivity, selectivity and wide
dynamic range, mass spectrometry (MS) has become the method
of choice to detect and establish the stoichiometry of histone
PTMs. Recent applications of MS also enabled the identification of
histone modifications from precise mass measurements on intact
protein ions and from on-line tandem MS spectra of the precursor
ions
23,24. In this report, we conducted a comprehensive label-free
quantitative proteomics study to profile histone modifications in
normal and cancer cell lines treated with different HDACi. Our
experimental strategy included a two pronged-approach that we
previously developed and validated to identify histone PTMs whose
abundance changes between wild-type and HAT mutant yeast
strains
25. Global changes in histone modifications are first deter-
mined from the mass profiles of intact histones. In a second step,
themodificationsitesandtheirrespectivestoichiometricchangesare
established by a combination of propionylation, trypsin digestion
and LC-MS/MS analyses. Bioinformatics tools are exploited to
rapidly sift through vast amounts of raw MS data. In this study, we
also designed two highly quantitative assays to accurately determine
the degree of modification of specific histone lysine residues, even
when the stoichiometry of acetylation is very low.
Results
Cell viability and cell cycle progression in response to HDACi.
HDACi can trigger apoptosis or cell cycle arrest in transformed
cell lines
9,18. Recent studies performed on leukemic cell lines in-
dicated that TSA globally increased H4 acetylation, an observation
that has been correlated with the induction of apoptosis in vitro and
in vivo
26,27. However, we wanted to analyze changes in histone acety-
lation under conditions where HDACi-treated cells did not lose
viability or cease to proliferate. We felt that the latter was important
because newly synthesized histones H3 and H4 are acetylated at
several lysine residues and incorporated into chromatin throughout
the genome during S-phase
28–31. Because new H3/H4 molecules are
very abundant in proliferating cells (50% of canonical histones pre-
sent in G2 cells have been newly synthesized during S phase), they
likely make a significant contribution to global levels of acetylation.
Accordingly, when their deacetylation is blocked by HDACi, the
acetylation of new histones would ultimately represent a significant
fraction of global acetylation levels.
We first examined whether HDACi treatment caused cell cycle
arrest using propidium iodide staining of DNA and flow cytometry
(FACS). Asynchronously growing K562 (human erythroleukemic)
cells exhibit three distinct levels of propidium iodide fluorescence
intensity, corresponding to DNA contents typical of cells in G1, S,
and G2/M phase (Fig. 1a).From the relative proportionof the peaks,
we found that no more than 20 % of control cells (i.e. cells that were
not treated with HDACi) were in S-phase. No significant change in
the FACS profile was observed for K562 cells exposed to 1 mM MS-
275 or SAHA (data not shown) for a period of up to 24 h (Fig. 1a).
Thus, at this concentration, these two HDACi did not trigger any
obvious cell cycle arrest. Consistent with this, K562 cell numbers
doubled during a 24 h period of exposure to either 1 mM MS-275
or1mMSAHA (datanotshown).Cellularviabilityandenergystatus
weremonitoredusingalamarblue,anon-fluorescentchemicalthatis
converted into fluorescent resorufin upon metabolic reduction
32.
Control cells and cells treated with either 1 mM MS-275 or 1 mM
SAHAfor48to72 hshowednomajordecreaseinviabilityorenergy
status (Fig. 1b and Supplementary Figs. 3–4). Thus, at the time when
histones were extracted for MS analysis (24 h), neither MS-275 nor
SAHA had caused appreciable proliferation arrest or lethality in
K562 cells. Our results are consistent with the fact that the same
concentrations of MS-275 or SAHA were not cytotoxic to several
other human cancer cell types
21. Normal human diploid fibroblasts
proliferated more slowly than K562 cells. IMR90 and WI38 cells had
doubling times of 48 and 72 h, respectively (Supplementary Fig. 1).
However, no decrease in cell viability was observed when SAHA or
MS-275 was added every 24 h for up to 72 hours (Supplementary
Figs. 3–4).
Global histone acetylation probed by intact mass profiling. We
first examined the changes in the molecular mass distribution of
intact histones following HDACi treatment using LC-MS on an
Agilent 6520 Q-TOF mass spectrometer. In each case, a total of
500 ng of acid extracts enriched in histones were injected onto the
LC-MS system. The total ion chromatogram (TIC) of histones from
K562cellsthatwerenottreatedwithHDACishowsthatcorehistones
H4, H2B, H2A and H3 eluted successively between 50 and 65 min
under our chromatographic conditions (Supplementary Fig. 5). For
convenience, mass spectra of core histones were transformed into
reconstructed molecular mass profiles and the deconvoluted spectra
obtained from extracts of cells treated with HDACi for 0, 6 or 24 h
were overlaid for comparison (Figs. 2a and 2b). The most significant
changes in the intact mass profiles wereobserved for histones H3 and
H4, rather than H2A or H2B (Figs. 2a and 2b). In eukaryotes, the
initiator methionine is removed from the four major types of core
histones: H2A, H2B, H3 and H4
33. Unlike H2A, H2B and H3, which
exist as multiple sequence variants, there is a single H4 protein
encoded by several genes
34. Essentially all H4 molecules are acety-
lated on their N-terminal amino groups
33. The N-terminally acety-
lated form ofH4isobserved at 11278 Da(Mcalc.: 11278.2 Da), along
www.nature.com/scientificreports
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additional acetylated forms at 11348, 11390, and 11432 Da. All these
H4 peaks were detected in both normal and transformed cells (Fig. 2
and Supplementary Fig. 4). A rapid increase in mono-, di- and tri-
acetylation was observed as early as 6 h after addition of SAHA to
K562 cells. Similar changes in acetylation patterns were observed in
K562 cells treated with MS-275, although the more highly acetylated
forms of H4 were only apparent after a 24 h exposure. Unlike
histone H2A and H4, virtually all the H3 molecules lack acetyla-
tion of the N-terminal amino group
39. In rapidly proliferating cells,
the replication-coupled histone H3 variants (H3.1 and H3.2) are
more abundant than the replication-independent H3.3 protein
35.
In K562 and normal diploid fibroblasts, the unmodified form of
H3.2 (Mcalc.: 15256.8 Da) was not detected, but that of H3.1
(Mcalc.: 15272.9 Da) was observed in low abundance at 15273 Da
(Fig. 2 and Supplementary Fig. 4). The intact mass profile of H3.1
revealed a heterogeneous distribution of molecular species with
incremental shifts of 114 and 142 Da, corresponding to multiple
forms of mono-methylation, acetylation and/or tri-methylation.
Treatment of K562 cells with SAHA or MS-275 caused an overall
shift to more highly acetylated forms. However, as observed for H4,
the most highly acetylated forms of H3 accumulated more rapidly
with SAHA (6 h) than with MS-275 (24 h). Based on intact mass
profiling, both SAHA and MS-275 predominantly increased the
acetylation of H3 and H4, whereas acetylation of H2A and H2B
was affected to a much lesser extent.
Todetermine whether HDACi hadsimilar effects onnormal cells,
we treated human diploid fibroblasts (IMR90 and WI-38 cells) with
the same concentrations of SAHA or MS-275 that were used
for K562 cells. A major fraction of histone acetylation likely occurs
in new histone molecules that are synthesized during S-phase.
Therefore,toensurethatnormalandtransformedcellswentthrough
asingle roundof S-phase inthe presence of HDACi,it wasnecessary
to treat IMR90 (48 h) and WI-38 (72 h) cells for longer times than
K562 cells (24 h). This is because normal cells proliferate more
slowly than K562 cells (Supplementary Fig. 1). As observed with
the K562 cell line, the viability of IMR90 or WI-38 cells was not
affected by HDACi concentrations of up to at least 1 mM (Sup-
plementaryFig.2and3).Theintactmassprofilesofhistonesderived
from HDACi-treated IMR90 and WI-38 cells showed global in-
creases in the acetylation patterns of H3 and H4 (Supplementary
Fig. 4 and data not shown). In addition, over a range of concentra-
tions where cells remained fully viable (from 0.125 mMu pt o1mM
SAHA or 1mM MS-275), both HDACi caused global increases in H3
and H4 acetylation that were comparable in normal cells and trans-
formed cells (data not shown).
Mapping modification sites by propionylation, tryptic digestion
and LC-MS/MS. To determine the degree of acetylation of specific
lysine residues following HDACi treatment, we purified individual
histones by reversed-phase HPLC and propionylated free lysine
residues prior to tryptic digestion and LC-MS/MS analyses
25. The
amount of protein in acid extracts containing histones was quan-
titatedusingtheMicro-BCAassay,andatotalof15mgwasseparated
by HPLC to isolate individual histones. A typical chromatographic
separation of histone extracts from K562 control cells resulted in
Figure 1 | Cellcycledistributionandviabilityof K562cells are notaffected by treatment with MS-275 orSAHA. (a)Propidium iodide (PI)staining of
DNAdetected by flow cytometry ofK562 cells treated for 6or 24 hours with1 mM ofthe class I HDACinhibitor MS-275. (b)Viability ofK562 cells after
continuous exposure to either 1mM SAHA or 1mM MS-275 (dissolved in DMSO) for 6 or 24 hours. The y-axis reflects the degree of reduction of alamar
blue by live cells monitored using fluorescence emission (see Experimental Section). Dead cells cannot reduce alamar blue. Error bars indicate three
independent alamar blue assays performed with each cell sample. CTL: Control with DMSO only.
www.nature.com/scientificreports
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mentary Figs. 6–7). We focused primarily on the identification of
modification sites on H3 and H4, since these core histones showed
the most significant global changes upon treatment with either
SAHA or MS-275. H3 and H4 histones from all cells and HDACi
conditions were derivatized with propionic anhydride, digested with
trypsin, and analyzed by LC-MS/MS on an LTQ-Orbitrap XL. Inter-
nal calibration using the polysiloxane ion at m/z 445.120029 (pro-
tonated (Si(CH3)2O))6) provided m/z measurements within 10 ppm
of the theoretical mass and facilitated unambiguous identification
of modifications with closely related masses (e.g. acetylation versus
tri-methylation).
Theinjectionoftrypticdigestsofindividualhistones,ratherthana
complex acid extract, maximized the number of histone peptides
detected and sequenced. This approach resulted in the identification
of a multitude of tryptic peptides including histones H3 and H4
peptides that originally contained free or acetylated lysine residues
invivo.Mapsrepresenting thepropertiesofallpeptideions(e.g.m/z,
charge, LC retention time, peak intensity) were obtained from each
raw LC-MS data file and aligned across replicates and HDACi treat-
ment conditions to assess changes in abundance of each identified
peptide ion. A list of all identified peptides and their abundance is
presented in Supplementary Tables 1 to 10. The relative standard
deviation observed for peptide ion intensities detected in all three
replicate LC-MS/MS analyses varied between 17 and 24 %, and was
consistent with the reproducibility attained by other quantitative
proteomics approaches
25,36. For all identified H3 and H4 tryptic pep-
tides,thestatisticalsignificanceandfoldchangeinabundancecaused
by either SAHA or MS-275 treatment is depicted in volcano plots
(Figs. 3a and 3b). The fold change was determined by calculating the
abundance ratio of the same peptide in histones from control and
HDACi-treated cells. A large proportion (,90% of all identified
peptides) were unaffected by treatment with either SAHA or MS-
275.Theseareclusteredneartheoriginofthevolcanoplots(p-values
. 0.05, fold change , 2). Two quadrants are delineated by dashed
boxes in the volcano plots. These contain peptides showing a statist-
icallysignificantfoldchangeineithercontrolorHDACi-treatedcells
for triplicate technical measurements (p-values , 0.05, fold change
. 2). MS/MS sequencing with either CID or ETD fragmentation
revealed that all the histone H3 residues that increased in acetylation
following HDACi treatment were located within the first 36 residues
of H3. Most notably, H3 K9,K 14,K 18 and K23 were primary sites of
hyperacetylation upon treatment with either SAHA or MS-275
(Supplementary tables 1–4 and 9). For example, Fig. 3c shows the
CID MS/MS spectrum of precursor peptide m/z 493.27
21, corres-
ponding to the tryptic peptide K9(ac)STGGK14(ac)APR, which is
highlighted by arrows in Fig. 3a. This peptide showed a 5- to 17-fold
increase in abundance upon SAHA or MS-275 treatment. Unex-
pectedly, thedimethylated tryptic peptide K27(me2)SAPATGGVK36
(me2)K37(pr)PHR identified by ETD fragmentation increased
approximately 2- to 4-fold in abundance under the same conditions
(Fig. 3a). The physiological importance of this finding is unclear, but
our result nonetheless indicates that HDACi can also increase the
abundance of histone lysine methylation. The combined use of CID
and ETD fragmentation facilitated the localization of modification
sites and enabled the identification of 41 differentially modified
Figure 2 | LC-MS analyses of intact histones derived from transformed cells. Intact histone profiles from K562 cells treated with SAHA (a) or MS-275
(b).Colortracesindicate histonespurified fromcontrolcells(black)or cellstreatedfor6 h(blue)or24 h(red)witheither 1mMSAHAor 1mMMS-275
(both dissolved in DMSO). Ctl: Control cells were treated with DMSO only.
www.nature.com/scientificreports
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chronously growing K562 cells. The use of decision tree driven
MS/MSsequencingwasusedtomaximizeproteinsequencecoverage
and identify any peptides that might have been missed if only one
fragmentation mode had been used
37. The majority of peptide ions
(70%) were identified using CID as doubly charged species, whereas
ETD detected 30 % of ions as triply or more highly charged species.
Volcano plots were also generated for histone H4 tryptic peptides
to identify residues showing the most significant changes in acetyla-
tion after SAHA (Fig. 3a) or MS-275 treatment (Fig. 3b). Following
propionylation, tryptic digestion of H4 yielded an N-terminal 14-
amino acid peptide (from residues 4 to 17) with four lysine residues
(K5,K 8,K 12, and K16). This 14-residue peptide was detected in mul-
tiple forms corresponding to different modification patterns. As
observed for H3, amino acids located within the N-terminal tail of
H4 were the most prominent targets of acetylation. Upon HDACi
treatment, we observed a gradual increase in the di- (K8,K 12 or K12,
K16 or K8,K 16), tri- (K8,K 12,K 16) and tetra-acetylated (K5,K 8,K 12,
K16) forms with the fully acetylated peptide clearly dominating after
exposuretoMS-275(7-and20-foldincreaseat6 hand24 h,respect-
ively). The mono-acetylated (K16 or K12) forms did not show a
significant change in abundance after exposure to any HDACi
(Supplementary tables 5–8 and 10). Fig. 3d shows the MS/MS spec-
trum for the tetra-acetylated tryptic peptide. Careful examination
of the fold changes in acetylation triggered by SAHA and MS-275
revealedinterestingdifferencesbetweenthesetwoinhibitors.Indeed,
treatment with 1 mM SAHA yielded a 17-fold increase in the tetra-
acetylated H4 tail peptide at 6 h with a subsequent reduction to
7-fold at 24 h, suggesting a limited long-term inhibitory activity of
SAHA compared with MS-275. The fact that MS-275 caused a more
robust long-term hyper-acetylation than SAHA was also obvious
from the intact mass profiles of H4 (Figs. 2a and 2b).
Figure 3 | HistoneH3andH4peptideionintensityprofilingusingvolcanoplots. K562cellswereeitherleftuntreated(CTL)ortreatedwitheither1mM
SAHA (a) or 1 mM MS-275 (b). Arrows show examples of modified histone peptides whose abundance is significantly affected by HDACi. Tandem MS
sequencing ofan N-terminal histone H3peptide (c),and an N-terminal histone H4 peptide(d), revealed acetylation sites that increased inabundance in
response to HDACi treatment.
www.nature.com/scientificreports
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quantification. Our profiling of tryptic peptides by LC-MS/MS
confirmed that lysine residues located within the N-terminal tails
of H3 and H4 were the most prominent acetylation sites following
HDACi treatment. Indeed, we observed very few acetylated tryptic
peptides within the globular domains of H3 and H4. This prompted
us to determine the stoichiometry of acetylation of some of these
sites using more sensitive and quantitative approaches. We were
particularly interested to look for H3K56ac because several re-
cent publications have implicated this modification in replication-
coupled nucleosome assembly, regulation of gene expression and
the DNA damage response
38–50. In addition, based on immunohisto-
chemistry, it has been argued that H3K56ac is a diagnostic and
prognostic marker of several different types of tumours
39. However,
studies of H3K56ac in human cells have been fraught with contro-
versy, particularly with regards to the role of this histone modifica-
tion in the DNA damage response
38,39,44,47,48,50, but also the identity of
the enzymes that acetylate or deacetylate H3K56
39–46,48,50.
To detect H3K56ac and determine its stoichiometry, we used
two approaches: MRM on an AB Sciex 4000 Q-Trap hybrid triple
quadrupole-linear ion trap mass spectrometer, and a high-resolution
quantitative approach on a Thermo Orbitrap-LTQ XL instrument.
An absolute quantitation method was developed using both an
H3K56ac synthetic peptide and an isotopically labeled standard
of the target tryptic peptide (YQK56(ac)STELLI*R), where I* is
a[
13C6
15N1]-labeled isoleucine residue. The unmodified (K56 pro-
pionylated) ion was detected in high abundance in the non-targeted
LC-MS/MS analyses described earlier. An MRM method was built
Figure 4 | Identification and quantitation of H3K56ac from K562 cells using targeted MRM. Tandem MS spectra of the light (a) and heavy (b)
YQK56(ac)STELLIR peptide standards at 10 mg/mL using enhanced product ion (EPI) scan. LC-MS/MS analysis (MRM) of the native H3K56ac peptide
(c) and the [
13C6
15N1-isoleucine]-labeled YQK56(ac)STELLI*R internal peptide standard (d) from a digest of histones isolated from K562 cells treated
with SAHA for 6 h.
www.nature.com/scientificreports
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4b). Four precursor/fragment ion pairs were selected to design an
MRM method for detection of the corresponding tryptic peptides
(see Supplementary information for details). We also monitored the
unmodified form (YQK56(pr)STELLIR), together with another H3
peptide (YRPGTVALR) to normalize for the amount of H3 present
in different samples. Following HPLC fractionation of acid extracts
(50 mg of starting material), our MRM assay was used to screen
for the presence of H3K56ac in K562 and HeLa cells treated with
various HDACi, including sodium butyrate, SAHA, MS-275, and
nicotinamide.Themodified K56acresiduewas detected atlowabun-
dance in all cell types and conditions tested, consistent with the
LC-MS/MS analyses described in the previous section. Figure 4c
shows LC-MS/MS results for H3K56ac in K562 cells treated with
SAHA for 6 h. Four MRM transition channels corresponding to the
formation of diagnostic y- andb-type fragmentions were monitored.
This strategy unambiguously identified a K562 cell-derived peptide
that contained H3K56ac and eluted at 26 min (Figs. 4c and 4d).
Figure 5 | LC-MS/MSanalysisofH3K56acfromK562cellsusinganLTQ-OrbitrapXLmassspectrometer. (a)Samples(seeExperimentalSection)were
prepared by mixing solutions of increasing concentrations (from 5 to 1000 pg/mL) of [
12C-isoleucine]-containing K56-acetylated peptide with a fixed
amount(100 pg/mL)ofinternalstandard(IS)peptide(YQK56(ac)STELLI*R),whereI*isa[
13C6
15N1]-labeledisoleucineresidue). They-axisisthepeak
heightabundanceratio(asdeterminedbyLC-MS)oftheYQK56(ac)STELLIRpeptide(containingonlythe[
12C]isotope)tothatofthe[
13C6
15N1]-labeled
internal peptide standard (IS). (b) Precursor ion mass spectrum (from LC-MS/MS analysis of histones derived from K562 cells treated with 1 mM SAHA
for 24 h) showing the detection of the native YQK56(ac)STELLIR peptide along with the [
13C6
15N1-isoleucine]-labeled internal standard. (c) MS/MS
spectrum of precursor m/z 646.86
21 from the analysis shown in (b). This spectrum confirms the identity of the natural peptide containing H3K56ac.
www.nature.com/scientificreports
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13C6
15N1-
isoleucine]-labeled internal standard (Figs. 4c and 4d). Second, as
expected, fragment ions from the K562 cell-derived H3K56ac pep-
tide were7 Thlighterthanthecorrespondingfragmentionsfromthe
internal standard containing [
13C6
15N1]-isoleucine (Figs. 4a and 4b).
The stoichiometry of acetylation was calculated using the peak areas
of the ion signal corresponding to the K56ac peptide divided by the
sumof the areasof the K56acandK56prpeptides.The stoichiometry
of H3K56ac in transformed human cells (K562 or HeLa) is shown in
Table1. Thestoichiometryof K56ac determined by MRM was0.03%
in all conditions tested, and did not change upon prolonged incuba-
tion with any of the HDACi that we tested.
We also performed high-resolution LC-MS analyses on the LTQ-
Orbitrap XL mass spectrometer to determine the stoichiometry of
H3K56ac in the same samples. The absolute amount of H3K56ac in
transformed cells was determined using a calibration curve spiked at
levels ranging from 5 to 1000 pg/mL, containing a constant amount of
the [
13C6
15N1]-labeled internal standard. In order to mimic, as closely
as possible, the reaction conditions used to process human histones
prior to MS, recombinant yeast histone H3 was propionylated and
Figure 6 | Antibodies supposedly specific for H3K56ac cross-react against other acetylated lysine residues of histone H3. (a) Immunoblot of core
histones purified from control and butyrate-treated HeLa cells (NaBut), as well as WT and rtt109D yeast cells, probed with an antibody from
Upstate/Millipore (07-677). (b) Immunoblot of core histones purified from control and butyrate-treated HeLa cells probed with Epitomics antibody
2134-1. Comparable amounts of histones from control and butyrate-treated cells were loaded as evidenced from the Coomassie Blue-stained gel.
(c) Immunoblot of core histones purified from yeast cells lacking the H3K56 acetyltransferase Rtt109 (rtt109D) or WT cells. In panels (a) to (c), the
‘‘H3K???ac’’ label indicates that the immunoblotting signal could not be ascribed to a specific acetylated lysine(s). (d) Amino acid sequences flanking
histone H3K56 and known acetylated lysines in the histone H3 N-terminal tail. Identical residues neighbouring acetylated lysines are highlighted.
(e) Immunoblot of core histones purified from butyrate-treated HeLa cells were probed with monoclonal antibodies from Epitomics (2134-1) or
Active Motif (61061) that were pre-incubated with different competitor peptides acetylated at specific lysine residues (histone H3 acetylated peptides).
Ø: No competitor peptide. Equal loading of histones from HeLa cells was verified either by stripping the blot and reprobing it with an antibody that
detects unmodified histone H3 (top panel) or by Ponceau S staining (bottom panel). (*) In addition to histone H3, the Active Motif antibody
recognized a band that migrated faster than H3. Detection of this faster migrating species was blocked by H3K9ac and H3K56ac competitor peptides,
suggesting that it is related to histone H3. In the same histone sample preparation, the Epitomics antibody did not recognize the band that migrated
faster than H3.
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peptide standard. The rationale was to generate reaction mixtures
containing similar sets of peptides and chemical species as those
produced during analysis of human cell-derived histones. Although
recombinant yeast histone H3 is less complex and devoid of PTM
33,
the conditions of propionylation and trypsin digestion are similar,
which helps tackle challenges to quantitation, such as chemicals that
co-elute with the H3K56ac peptide of interest and might suppress its
ionization. This is particularly important in this case because of the
very low abundance of the H3K56ac peptide. The first residue of the
yeast H3 tryptic peptide containing K56 is a Phe, instead of a Tyr
residue in human H3. Hence, H3K56 tryptic peptides derived from
yeast histones do not interfere with our quantitative analysis. Our
calibration curve showed excellent linearity (r
2 5 0.9993) over the
range of concentrations examined (Fig. 5a). We detected the authen-
ticH3K56acpeptideatalevelapproachingtheinstrumentaldetection
limit in all the human histone samples. An example of the precursor
ion mass spectrum for the H3K56ac peptide derived from K562 cells
treatedwithSAHAfor24 hisshowninFig.5b.Themassesmeasured
for the light and heavy labeled doubly protonated peptides were
respectively within 1 ppm and 5 ppm of those calculated from their
correspondingtheoreticalmasses.AnMS/MSspectrumthatconfirms
the identity of the precursor ion corresponding to the human K56ac
peptide is shown in Fig. 5c. The H3K56ac stoichiometry was deter-
mined from the ratio of the peak height of the doubly protonated
K56ac tryptic peptide divided by the sum of the peak heights for the
K56ac and K56pr peptides. The results from high-resolution LC-MS
analyses are shown in Table 1, together with the absolute amount of
tryptic peptide detected. The amount of H3K56ac present in all con-
ditions ranged from 150 to 370 attomol, while the acetylation stoi-
chiometry varied from 0.05–0.08%. Consistent with our MRM exper-
iments, no significant change in the stoichiometry of H3K56ac was
detected under any of the conditions examined, and even after pro-
longed incubation (up to 24 h) of K562 or HeLa cells with HDACi
that target different classes of deacetylases (Table 1). Thus, based on
two different quantitative MS experiments, we find that the stoichi-
ometry of H3K56ac (roughly 0.04%) is considerably lower than prev-
iously reported (1%)
39,49. In addition, unlike other sites of acetylation,
H3K56ac did not increase in response to several HDACi (Table 1).
This was very intriguing because two of the HDACi that we used in
our MS experiments, namely sodium butyrate and nicotinamide,
were previously shown to increase H3K56ac based on immunoblot-
ting
39,48. This prompted us to investigate the specificity of three com-
mercially available antibodies that were previously used to detect
H3K56ac in human cells
38,39,42–48. For these experiments, the same
histone samples were analyzed either by MS or immunoblotting.
The amounts of acid-extracted histones often used in immunoblots
are sufficiently large to be readily detected byPonceau S staining after
histone transfer to nitrocellulose or PVDF membranes
39,46. As prev-
iously reported
39,46,48, we found that, under those conditions, sodium
butyrate treatment of HeLa cells strongly increased the signal
obtained with antibodies supposedly specific for H3K56ac (Figs. 6a
and 6b). However, with amounts of histones detectable by Ponceau S
or Coomassie blue staining, the same antibodies also detected a con-
siderable signal in histones purified from yeast rtt109D mutant cells
(Figs. 6a and 6c). In yeast, Rtt109 is the main enzyme that acetylates
H3K56. Consistent with this, as judged by MS, H3K56ac is virtually
absentfromrtt109nullmutantcells
25.Therefore,theimmunoblotting
signals detected by commercial antibodies in histones purified from
rtt109D mutant yeast cells (Figs. 6a and 6c) must be derived from
modifications other than H3K56ac. Intriguingly, three of the six
known acetylation sites located in the N-terminal domain of histone
H3 share some sequence similarity with residues flanking H3K56
(Fig. 6d). Based on this, we hypothesized that commercial antibodies
raised against H3K56-acetylated peptides might show some degree of
cross-reactivity against abundant acetylation sites that bear similarity
to residues flanking H3K56. To address this possibility, we obtained
a set of six synthetic peptides, each containing a single acetylated
lysine residue. These peptides represent all the known acetylation
sites within the first 30 amino acid residues of histone H3 (Sup-
plementary Fig. 7). Each peptide was incubated with commercial
antibodies raised against H3K56ac to determine whether they would
block the ability of the antibodies to detect signals in immunoblots of
histones purified from human cells. As control for a peptide that
should block each antibody, we used a K56-acetylated synthetic pep-
tide. As shown in Fig. 6e, in addition to the K56-acetylated peptide,
three ofthecompetitorpeptides derived fromtheN-terminal domain
of H3 either abolished or significantly reduced the immunoblotting
signals obtained with histones purified from butyrate-treated HeLa
cells. The K9ac peptide was the best competitor, but the K4ac and
K27ac peptides also blocked some of the commercial antibodies that
were reportedly H3K56ac-specific (Fig. 6e). This was true for two
monoclonal antibodies (Fig. 6e) and a polyclonal antiserum from
Millipore (data not shown). The latter antibody is no longer com-
mercially available but was previously used in several publications.
Interestingly, the acetylated peptides that blocked the commercial
antibodies were those that shared sequence similarity with residues
flanking H3K56. In contrast, peptides acetylated at H3K14, H3K18
or H3K23, which lack similarity with residues that flank H3K56,
all failed to block the antibodies in our competition experiments
(Figs. 6d and 6e). In cells treated with SAHA, we estimated by MS
that the stoichiometry of H3K9ac (about 33%) is roughly 800-fold
higher than that of H3K56ac (0.04%). These findings, combined with
the fact that two quantitative MS approaches did not reveal an
increase in H3K56ac, even after extended periods of incubation with
several HDACi (Table 1), leadus toconclude that several commercial
antibodies previously used to study H3K56ac in human cells cross-
react with sites of acetylation other than histone H3K56 and, particu-
larly, H3K9. It is noteworthy that several studies reported that the
abundance of H3K9ac and H3K56ac changed in the same direction
Table 1 | Stoichiometry and amounts of H3K56ac detected in transformed cells exposed to different HDACi
Conditions
Amount of H3 K56(ac) peptide
detected LTQ-Orbitrap (attomol)
Stoichiometry of
H3 K56(ac) (%) LTQ-Orbitrap
Stoichiometry of H3
K56(ac) (%) MRM
K562, control (0 h)
K562, control (6 h)
K562, control (24 h)
K562, MS-275 (6 h)
K562, MS-275 (24 h)
K562, SAHA (6 h)
K562, SAHA (24 h)
K562, nicotinic acid (12 h)
K562, nicotinamide (12 h)
K562, nicotinamide (24 h)
HeLa, butyrate (24 h)
160
198
224
169
297
206
164
201
205
291
367
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.07
0.08
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
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41,43–46.G i v e nt h el a r g e
stoichiometric excess of H3K9ac over H3K56ac, and the fact that
antibodies raised against H3K56ac cross-react with H3K9ac, we sug-
gest that these manuscripts described changes in the abundance of
H3K9ac, rather than H3K56ac.
Discussion
Our two-pronged approach to identify global changes in histone
acetylation that arise from HDAC inhibition has led to three unex-
pected findings about the dynamics of histone acetylation in human
cells. First, HDACi with either hydroxamic acid (SAHA) or benza-
mide (MS-275) inhibitory moieties both trigger global hyperacety-
lation of H3 and H4 in normal diploid fibroblasts and several
transformed cell lines (K562, HeLa, HEK293T, and U937). Second,
even when SAHA and MS-275 elicit global increases in H3 and H4
N-terminaltailacetylationinnormaldiploidfibroblasts,thecellsdid
notloseviability(SupplementaryFigs.2,3and4).Inthefuture,itwill
be interesting to determine if this is also the case in cancer cells and
whether the cytotoxicity of SAHA and MS-275 has anything to do
withtheirabilitytogloballyenhancehistoneH3andH4acetylation
9.
Third, the development of two robust MS-based quantitative assays
to determine the stoichiometry of histone H3K56ac in control and
HDACi-treatedcellshasrevealedsomehighlyunexpectedproperties
of this modification in human cells that are distinct from those of
H3K56ac in yeast.
InS.cerevisiaeandotheryeasts,H3K56acisveryabundantduring
S-phase and G2. This is because essentially all the new H3 molecules
are K56-acetylated prior to their deposition into nascent chromatin
and subsequently deacetylated in late G2 or M-phase
4,51. Our data
demonstrate that this is clearly not the case for H3K56ac in human
cells. In contrast to the acetylation of many other residues in the H3
andH4N-terminaldomains
52,itispuzzlingthatprolongedexposure
to either class I/II or class III HDACi did not increase the stoichi-
ometry of H3K56ac in transformed human cells. We cannot exclude
the possibility that H3K56ac might slightly increase above 0.03%
upon HDACi treatment. However, the very low stoichiometry of
H3K56ac in human cells makes it unlikely that this modification
can significantly contribute to genome-wide deposition of newly
synthesized histone molecules. Our findings certainly do not rule
out the possibility that H3K56ac may have an important function
inhumancells.Astoichiometryof0.03%correspondstoroughlyone
K56-acetylated H3 molecule every 1665 nucleosomes (or roughly
every 333 Kb, assuming an average nucleosome repeat length of
200 bp). Given the size of the genome of a diploid human cell
(roughly 6310
9 bp), there would be approximately 18000 K56-
acetylated H3 molecules per cell. Despite the intriguing absence of
H3K56 deacetylation, some of these molecules may occur at specific
chromosomal loci where H3K56ac might play important functions
in either the DNA damage response or the regulation of gene
expression
36,39,40,42–50,53. However, we would like to emphasize that
reports of the presence of H3K56ac at specific loci (sites of DNA
damage or gene regulatory elements), as determined by immuno-
fluorescence or chromatin immunoprecipitation (ChIP) assays, are
questionable because the H3K9 and H3K56 epitopes are related in
sequenceandH3K9acisfarmoreabundantthanH3K56acinhuman
cells.Ourstudyunderscoresthefactthatevenpartialcross-reactivity
ofantibodiescanleadtoerroneousdatainterpretationwhenepitopes
contain modified amino acids whose flanking residues share se-
quence similarity with other segments of the same protein. This
may be an important issue for lysine residues in the N-terminal
domain of histone H4, where three of the four known acetylated
lysines reside in the sequence context GKG. As we demonstrated
for H3K9ac and H3K56ac, this is particularly problematic when
the stoichiometry of modification of the residue that should not
be recognized by the antibody is much higher than the extent of
modification of the intended target residue. To test whether this
might be the case, and avoid false conclusions due to antibody
cross-reactivity, we recommend quantitative mass spectrometry as
ameanstoaddressthestoichiometryofmodificationofresiduesthat
are flanked by similar amino acid sequences. This is particularly
important for studies of vertebrate cells, where it is not currently
possible to mutate specific histone residues in order to rigorously
prove antibody specificity in immunofluorescence or ChIP experi-
ments. This is also a major issue in immunohistochemistry. Overall,
our findingsdemonstrate the importance of quantitative MS to deter-
mine the stoichiometry of specific protein modifications under a
variety of physiological conditions and use this information to for-
mulate hypotheses regarding the function(s) of these modifications.
Methods
Immunoblotting. Histone proteins were run through SDS-polyacrylamide gels and
transferred onto PVDF membranes. After transfer, the presence of equal amounts of
core histones was assessed using either Ponceau S staining or by immunoblotting
using an antibody against non-modified histone H4. The membranes were then
probed with primary antibodies raised against H3K56ac peptides (Active Motif
mouse monoclonal antibody 61061, Upstate/Millipore rabbit polyclonal antibody
07-677 or Epitomics rabbit monoclonal antibody 2134-1) overnight at 4uC. After a
12–14 h incubation with primary antibodies, blots were washed extensively in
Tris-buffered saline (25 mM Tris-HCl pH 8.0, 137 mM NaCl, 3 mM KCl). After
incubation with secondary antibodies (anti-rabbit IgG coupled to horseradish
peroxidase) for one hour at room temperature, the blots were washed extensively in
Tris-bufferedsaline(25 mMTris-HClpH8.0,137 mMNaCl,3 mMKCl)containing
0.1% (w/v) Tween-20, and antibody binding was detected by enhanced
chemiluminescence (GE Healthcare). Synthetic peptides were mixed at a 1000:1
molar ratio with purified antibodies to determine whether they blocked the ability of
antibodies to detect acetylated histones.
Sample preparation and protein digestion. The total protein content of histone-
enrichedacidextractswasmeasuredwiththeMicro-BCAassay.Approximately15mg
ofstartingmaterialwasseparatedusinganAgilent1100 HPLCsystemequippedwith
a micro-fraction collector. Separations were performed on a Jupiter microbore C18
column (3 mm, 300 A ˚; 15031 mm i.d.) with a solvent system consisting of 0.1% TFA
in water (v/v) (solvent A), and 0.1% TFA in acetonitrile (v/v) (solvent B). Gradient
elution was performed from 5 to 70% B in 60 min at 15 mL/min. Fractions were
collected in a 96-well plate at 20 second intervals and fractions representing
individual histone peaks were pooled together. For the targeted analysis of H3K56ac,
approximately 50 mg of starting material was separated using an Agilent 1200 HPLC
system equipped with a fraction collector. Separations were performed on an ACE
standardboreC8column(5mm,300A ˚;15034.6 mmi.d.)at0.7 mL/min.HistoneH3
fractions were collected in 2 mL Eppendorf tubes at 1 minute intervals. Multiple
fractions were pooled together as described above. Histones were prepared and
digestedaspreviouslydescribed
25.LCfractionsweredriedinaSpeed-Vacevaporator
and resuspended in 0.1 M ammonium bicarbonate buffer (without pH adjustment).
Intact histones were derivatized in a 1:1 volume ratio with a propionic anhydride
reagent. After a 30 minute derivatization period at room temperature, samples were
evaporated a second time, resuspended in 0.1 M ammonium bicarbonate, and
digestedovernightat37uCusing1mgoftrypsin.Sampleswereacidifiedwith5%TFA
in water (v/v) prior to LC-MS analysis. Under our conditions, propionylation
proceeded nearly to completion, as judged by negligible trypsin cleavage at non-
propionylated lysine residues, which we verified by MS. Near complete
propionylation of non-modified lysine residues is important to determine the
accurate stoichiometry of histone acetylation because trypsin would otherwise cleave
after non-modified lysines. This would obviously lead to an over-estimation of the
fraction of histone molecules that are acetylated at a given site.
Intact histone profiling. Intact histone analysis was performed on an Agilent 6520
Q-TOF mass spectrometer equipped with a nanoelectrospray interface. The
instrumentwasoperatedinpositiveionmode(2800 Vatinterface)andscannedfrom
m/z 400 to 1600. Equivalent amounts of histone acid extracts were diluted down to a
concentration of 100 ng/mL with the initial LC-MS mobile phase (see below). An
aliquotwasinjectedontoanin-housepackedcapillaryC18trappingcolumn(4 mm3
360 mm I.D.) for 3 min at 10 mL/min using a loading solvent (95:5 water:acetonitrile
containing 0.2% formic acid (v/v)). Histones were eluted onto the C18 analytical
column (100 mm 3 150 mm i.d.) using 0.2% formic acid in water (v/v) (solvent A),
and0.2%formicacidinacetonitrile(v/v)(solventB).Gradientelutionwasperformed
from5to90%Bin60 minat600 nL/min.Intacthistonemassprofilesweregenerated
from acquired mass spectra using the MaxEnt1 deconvolution algorithm of the Mass
Hunter software.
Ion profiling and peptide sequencing by LC-MS/MS. LC-MS/MS analyses were
performed using an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific,
San Jose, CA) equipped with a nanoelectrospray interface. Tryptic digests were
injected in triplicate using an Eksigent nano 2D-LC system. The same columns and
solventsystemswereusedasdescribedaboveintheintactmassprofilingsection.The
www.nature.com/scientificreports
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resolution set to 60 000, with a target value of 1.0 3 10
6. For tandem MS/MS
sequencing, the LTQiontrapwasscanned from m/z50to2000, withatarget valueof
1.0 3 10
4. One full survey scan in the Orbitrap was followed by data dependant MS/
MS acquisition on the three most intense ions. A decision tree based on peptide m/z
ratio and charge state was used to trigger either CID or ETD fragmentation
37.A
normalized collision energy of 35 was used to generate fragment ions in the LTQ by
CID, while a 100 ms activation time was used for ETD ion-ion reactions. All MS/MS
spectra of modified histone peptides are provided as supplementary Figures.
All raw data files (.raw) from triplicate injections on the LTQ-Orbitrap XL mass
spectrometer were converted into peptide maps using Mass Sense (version 2.5), an
in-house peptide detection software used to identify peptides based on m/z values,
retention time, abundance, and charge state. An intensity threshold of 10 000 counts
was set as cutoff for precursor ion peak detection. Segmentation analysis was per-
formedbyclusteringthepeptideionsidentifiedineachtreatmentconditionbasedon
their respective m/z ratio, charge, and LC retention time using an m/z tolerance of
60.02Thanda timedifference of1 min.NormalizationofLCretention timeisthen
performedontheinitialpeptideclusterlistusingadynamicandnonlinearcorrection.
Once clustered, all peptide intensities were averaged and a mean ratio was calculated
to generate a correction factor used to normalize for changes in abundance and
differences in amount of peptide loaded. Normalized intensities are then used to
generate a volcano plot for differential histone PTM expression profiling. Raw data
files were converted to Mascot generic files (.mgf) using Mascot Distiller (version
2.2.1) and Mascot Daemon (version 2.2.2). A mass tolerance of 0.02 Th was used for
the precursor ions, and 0.5 Th for the fragment ions. A maximum of 9 missed
cleavages was permitted during the Mascot searches. The following variable mod-
ifications were included in the search parameters: acetylation, methylation1pro-
pionylation, dimethylation, and trimethylation, and propionylation of lysine
residues, methylation of arginine residues, phosphorylation of serine, threonine and
tyrosine residues, and oxidation of methionine residues. Manual MS/MS spectra
verificationwasperformedoneachmodifiedpeptidewithMascotscoresgreaterthan
20 to confirm the sequence assignment. Mascot searches were downloaded from the
Mascot server into an Excel spreadsheet, from which redundant and low scoring
peptideswereremoved.AllMS/MSspectracorrespondingtomodifiedhistonetryptic
peptides are provided as supplementary information.
Targeted analysis of H3K56ac by multiple reaction monitoring and absolute
quantitation. Stock solutions at 1 mg/mL in deionized water were prepared for two
K56-acetylated synthetic peptides: a peptide containing only [
12C] and a peptide
where a leucine was [
13C,
15N]-labeled (see below). Unmodified yeast histone H3 was
expressed in E. coli, purified as described
54, and resuspended in 0.1 M ammonium
bicarbonate buffer. Approximately 3 mg of recombinant yeast histone H3 was
propionylated, digested, and spiked with increasing amounts of synthetic human
H3K56ac peptide (YQK(ac)STELLIR) ranging from 5 to 1000 pg/mL. To each
solution, a constant amount of the isotopically labeled internal standard (IS) peptide
(YQK(ac)STELLI*R, wherein I* is a [
13C6
15N1]-labeled isoleucine), was added to
obtain a final concentration of 100 pg/mL IS in each vial. A 20-mL aliquot of each
mixture was injected onto the LTQ-Orbitrap XL mass spectrometer, and analyzed
using the same parameters as described in the LC-MS/MS analysis section.
A multiple reaction monitoring (MRM) method was designed to detect and
quantify the human H3K56ac tryptic peptide using an AB Sciex 4000 Q-trap hybrid
triple quadrupole-linear ion trap mass spectrometer equipped with a Nanospray II
interface. Working solutions of human K56ac peptide and its labeled analogue were
prepared at a concentration of 10 mg/mL in 50550 water:methanol with 0.2% formic
acid (v/v/v) for nanoelectrospray infusion. Source parameters were optimized by
constant infusion of the working solutions at 600 nL/min. The electrospray voltage
was set to 3800 V, with a declustering potential of 120 V, and an optimized collision
energy of 32 V. The four most intense ions were chosen to build MRM transitions
within the Analyst software. All MRM transitions used in this study are provided in
the Supplementary Methods. Both H3K56ac and its non-modified counterpart
(H3K56pr) were monitored in parallel; another H3 tryptic peptide (YRPGTVALR)
wasalsomonitoredtonormalizefortheamountofpeptideloadedandfluctuationsin
the electrospray response.
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